Fu Ke, Wang Cheng, Ma Cheng, Zhou Honglin, Li Yunxia
State Key Laboratory of Southwestern Chinese Medicine Resources, Key Laboratory of Standardization for Chinese Herbal Medicine, Ministry of Education, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Front Pharmacol. 2021 Nov 4;12:771459. doi: 10.3389/fphar.2021.771459. eCollection 2021.
Liver diseases have been a common challenge for people all over the world, which threatens the quality of life and safety of hundreds of millions of patients. China is a major country with liver diseases. Metabolic associated fatty liver disease, hepatitis B virus and alcoholic liver disease are the three most common liver diseases in our country, and the number of patients with liver cancer is increasing. Therefore, finding effective drugs to treat liver disease has become an urgent task. Chinese medicine (CM) has the advantages of low cost, high safety, and various biological activities, which is an important factor for the prevention and treatment of liver diseases. This review systematically summarizes the potential of CM in the treatment of liver diseases, showing that CM can alleviate liver diseases by regulating lipid metabolism, bile acid metabolism, immune function, and gut microbiota, as well as exerting anti-liver injury, anti-oxidation, and anti-hepatitis virus effects. Among them, Keap1/Nrf2, TGF-β/SMADS, p38 MAPK, NF-κB/IκBα, NF-κB-NLRP3, PI3K/Akt, TLR4-MyD88-NF-κB and IL-6/STAT3 signaling pathways are mainly involved. In conclusion, CM is very likely to be a potential candidate for liver disease treatment based on modern phytochemistry, pharmacology, and genomeproteomics, which needs more clinical trials to further clarify its importance in the treatment of liver diseases.
肝脏疾病一直是全球人民面临的共同挑战,威胁着数亿患者的生活质量和安全。中国是肝病大国。代谢相关脂肪性肝病、乙型肝炎病毒和酒精性肝病是我国最常见的三种肝脏疾病,且肝癌患者数量不断增加。因此,寻找治疗肝病的有效药物已成为一项紧迫任务。中药具有成本低、安全性高和多种生物活性等优点,是防治肝脏疾病的重要因素。本综述系统总结了中药在肝病治疗中的潜力,表明中药可通过调节脂质代谢、胆汁酸代谢、免疫功能和肠道微生物群,以及发挥抗肝损伤、抗氧化和抗肝炎病毒作用来缓解肝病。其中,主要涉及Keap1/Nrf2、TGF-β/SMADS、p38 MAPK、NF-κB/IκBα、NF-κB-NLRP3、PI3K/Akt、TLR4-MyD88-NF-κB和IL-6/STAT3信号通路。总之,基于现代植物化学、药理学和基因组蛋白质组学,中药很可能是肝病治疗的潜在候选药物,这需要更多的临床试验来进一步阐明其在肝病治疗中的重要性。